# Open-label Extension Study in Participants With Early Alzheimer's Disease

> **NCT07105709** · PHASE2 · RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 220 (estimated)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** GSK4527226

## Key facts

- **NCT ID:** NCT07105709
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-14
- **Primary completion:** 2028-09-15
- **Final completion:** 2028-12-08
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2026-02-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07105709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07105709, "Open-label Extension Study in Participants With Early Alzheimer's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07105709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*